Attention Deficit Hyperactivty Disoerder
Conditions
Interventions
Trade Name: Medikinet CR, 10, 20, 30 en 40 mg, capsules met verlengde afgifte, hard.
Pharmaceutical Form: Capsule, hard
Pharmaceutical form of the placebo: Capsule, hard
Route of administration of the
Sponsors
ZonMw zorg voor jeugd-effecten en kosten
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. ADHD diagnosis according to the DSM-IV criteria (alle subtypes) 2. Age between 8 and 13 years 3. IQ above 80 4. No neurological disorder Are the trial subjects under 18? yes Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: No major disability
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The main objective of the trial is to answer the question is if neurofeedback and exercise are comparable in efficacy with (medication, methylphenidate) for treating ADHD.;Secondary Objective: The secondary objective is to get insight in how these interventions (neurofeedback, exercise and methylphendiate) give rise to improvements in behavior. ;Primary end point(s): Improvements in behaviour, neurocognition and cortical regulation (Electro-encephalography/Event-related potentials). | — |
Countries
Netherlands
Outcome results
None listed